Streetbeat News

AEON

AEON Biopharma, Inc.

http://www.aeonbiopharma.com

Industry

Biotechnology

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Open

0.61

Mkt cap

24M

Volume

130K

High

0.66

P/E Ratio

-4.75

52-wk high

17.17

Low

0.60

Div yield

N/A

52-wk low

0.60

Several healthcare stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Nuwellis, Streamline Health Solutions, and Inhibikase Therapeutics, while Windtree Therapeutics and Ontrak were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 4:31 pm

Several health care stocks experienced significant price movements during Friday's intraday session. Notable gainers included Cue Biopharma, Capricor Therapeutics, and Entero Therapeutics, while Impact BioMedical and Avinger were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:32 pm

HC Wainwright & Co. has reiterated its Buy rating on AEON Biopharma, maintaining a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 10:20 am

AEON Biopharma has announced alignment with the FDA on the next steps for the 351(k) regulatory pathway to approve ABP-450 as a biosimilar, using BOTOX as the reference product.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:05 pm

Aeon Biopharma has filed with the SEC for a Class A common stock offering, aiming to raise up to $50 million.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:30 pm

HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but lowered the price target from $6 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:15 pm

AEON Biopharma (AMEX:AEON) reported Q2 2024 GAAP EPS of $4.22, significantly surpassing the estimated $(0.19) by 2321.05%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:13 pm

Shares of The Charles Schwab Corporation (NYSE:SCHW) fell over 7% following their second-quarter results, which showed a decline in adjusted net income and EPS. Other stocks such as Yoshitsu Co., Ltd (NASDAQ:TKLF) and Silo Pharma, Inc. (NASDAQ:SILO) saw significant gains, while Cyngn Inc. (NASDAQ:CYN) and Autonomix Medical, Inc. (NASDAQ:AMIX) experienced notable declines.

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 5:06 pm

Shares of Match Group (NASDAQ:MTCH) rose sharply in pre-market trading due to Starboard Value's 6.5% stake and potential advocacy for a sale. Other notable pre-market movers include Conduit Pharmaceuticals (NASDAQ:CDT), Meiwu Technology (NASDAQ:WNW), and AEON Biopharma (NYSE:AEON).

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 9:51 am

SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares fell 12.2% after announcing a workforce reduction of 400 employees. Other notable stock movements include Autonomix Medical, Inc. (NASDAQ:AMIX) climbing 148% and Trump Media & Technology Group Corp. (NASDAQ:DJT) rising 32.8% following an attempted assassination of Donald Trump.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 5:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.